Cargando…

Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia

Clozapine is effective in treatment-resistant schizophrenia; however, adverse effects often result in discontinuation of clozapine therapy. Many of the side-effects are associated with pharmacokinetic variations; therefore, the expression of major clozapine-metabolizing enzymes (CYP1A2, CYP3A4) in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menus, Ádám, Kiss, Ádám, Tóth, Katalin, Sirok, Dávid, Déri, Máté, Fekete, Ferenc, Csukly, Gábor, Monostory, Katalin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718230/ https://www.ncbi.nlm.nih.gov/pubmed/33277605 http://dx.doi.org/10.1038/s41598-020-78474-0

Ejemplares similares

Potential Role of Patients’ CYP3A-Status in Clozapine Pharmacokinetics
por: Tóth, Katalin, et al.
Publicado: (2017)

Optimization of Clonazepam Therapy Adjusted to Patient’s CYP3A Status and NAT2 Genotype
por: Tóth, Katalin, et al.
Publicado: (2016)

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients
por: Fekete, Ferenc, et al.
Publicado: (2023)

Relevance of CYP2C9 Function in Valproate Therapy
por: Monostory, Katalin, et al.
Publicado: (2019)

Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects
por: Fekete, Ferenc, et al.
Publicado: (2021)

CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function
por: Mangó, Katalin, et al.
Publicado: (2022)

End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s
por: Déri, Máté Tamás, et al.
Publicado: (2020)

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)

CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity
por: Fekete, Ferenc, et al.
Publicado: (2022)

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma
por: Mangó, Katalin, et al.
Publicado: (2023)

Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients
por: Incze, Evelyn, et al.
Publicado: (2023)

Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles
por: Fodor-Kardos, Andrea, et al.
Publicado: (2020)

Adverse events in a newborn on valproate therapy due to loss-of-function mutations in CYP2C9
por: Nagy, Andrea, et al.
Publicado: (2015)

Homocysteine Levels in Patients with Schizophrenia on Clozapine Monotherapy
por: Wysokiński, Adam, et al.
Publicado: (2013)

Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
por: Montgomery, Adam, et al.
Publicado: (2023)

Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents
por: Grover, Sandeep, et al.
Publicado: (2016)

The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia
por: Rodrigues-Silva, Christielly, et al.
Publicado: (2020)

In Vitro Pharmacokinetic Behavior of Antiviral 3-Amidinophenylalanine Derivatives in Rat, Dog and Monkey Hepatocytes
por: Lányi, Katalin, et al.
Publicado: (2023)

USE OF CLOZAPINE IN CHILDHOOD SCHIZOPHRENIA
por: Srinivasan, T.N., et al.
Publicado: (1997)

Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia
por: Yin, Feiyan, et al.
Publicado: (2023)

Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy
por: Wysokiński, Adam, et al.
Publicado: (2014)

Fronto-thalamic structural and effective connectivity and delusions in schizophrenia: a combined DTI/DCM study
por: Csukly, Gábor, et al.
Publicado: (2021)

Long-Chain Polyunsaturated Fatty Acids in Inborn Errors of Metabolism
por: Fekete, Katalin, et al.
Publicado: (2010)

From basic perception deficits to facial affect recognition impairments in schizophrenia
por: Marosi, Csilla, et al.
Publicado: (2019)

Impaired mixed emotion processing in the right ventrolateral prefrontal cortex in schizophrenia: an fMRI study
por: Szabó, Ádám György, et al.
Publicado: (2017)

Clozapine Induced Disturbances in Hepatic Glucose Metabolism: The Potential Role of PGRMC1 Signaling
por: Cao, Ting, et al.
Publicado: (2021)

Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4
por: Danek, Przemysław J., et al.
Publicado: (2020)

Effectiveness of clozapine in treatment-resistant schizophrenia
por: Raguraman, Janakiraman, et al.
Publicado: (2005)

Clozapine: Improvement of Negative Symptoms of Schizophrenia
por: Khan, Afaque H, et al.
Publicado: (2017)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

Management of patients with Clozapine Resistant Schizophrenia
por: Rajendran*, Nithya Ragavi, et al.
Publicado: (2022)

Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia
por: Tseng, Ping-Tao, et al.
Publicado: (2022)

Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study
por: Johannsen, Claas-Frederik, et al.
Publicado: (2022)

Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients
por: Hribkova, Hana, et al.
Publicado: (2022)

Emotion-Related Visual Mismatch Responses in Schizophrenia: Impairments and Correlations with Emotion Recognition
por: Csukly, Gábor, et al.
Publicado: (2013)

Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia
por: Willcocks, Isabella R., et al.
Publicado: (2021)

A False Case of Clozapine-Resistant Schizophrenia
por: Maia-de-Oliveira, J. P., et al.
Publicado: (2010)

REFRACTORY SCHIZOPHRENIA, CLOZAPINE AND EPILEPSY : MANAGEMENT STRATEGIES
por: Guha, Prathama, et al.
Publicado: (1998)

AN OPEN STUDY OF CLOZAPINE IN THE TREATMENT OF RESISTANT SCHIZOPHRENIA
por: Desai, Neena, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_pj5h1lm4g84511gs9q13rknut3